@Nerdag, thanks for your Straw.
I think the announcement highlights profitability and scalability issues. They have churned through cash once again with customer receipts far too low for my liking. I forecasted that this quarterly would be positive, with all signs pointing to ramped up production for Abiomed. I was wrong - revenue went backwards!
Given cash burn rates, a capital raise is once again around the corner. Can you imagine the discount the company will have to offer potential investors to attract interest and raise enough capital? I am not sticking around to find out.
This was always a speculative move on my behalf, but the turnaround hasn't occured - in fact business operations have declined - and with NanoDX pulling the pin, the risk far outweighs the reward in my opinion.
DISC - SOLD